Retatrutide UK: The Triple Hormone Weight Loss Injection Explained (GLP-1 + GIP + Glucagon) Retatrutide is one of the most talked about next generation weight loss injections because its designed to target three hormone pathways linked to appetite, blood sugar control and energy use (unlike Wegovy and Mounjaro, which target one or two)
This implies that liraglutide, while effective for weight reduction, comes at a higher cost per unit of weight loss than semaglutide
This protective mechanism makes it a valuable subject in research related to skin photoprotection and anti-aging dermatology
It makes the treatment convenient and easy to self-administer
Summary: Retatrutide FDA Status Retatrutide is not FDA-approved and won't be for at least another year It's in Phase 3 trials (TRIUMPH program) with results expected in late 2026 FDA approval is projected for 20272028 Phase 2 data showed 24.2% weight loss , better than any approved GLP-1 medication Current access: clinical trials (free), compounded retatrutide ($200$500/mo), or research peptides ($150$500/mo) When approved, retatrutide will be the first triple-agonist obesity medication on the market References Jastreboff AM, Aronne LJ, Ahmad NN, et al
